November 17, 2022
RFA-DK-22-019 - Type 1 Diabetes Mellitus Stakeholder Engagement Innovation Center to Advance Health Equity (U2C Clinical Trial Not Allowed)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The purpose of this notice is to inform applicants of a change to the Key Dates and correction of application instructions for RFA-DK-22-019 "Type 1 Diabetes Mellitus Stakeholder Engagement Innovation Center to Advance Health Equity (U2C Clinical Trial Not Allowed)". This Funding Opportunity Announcement (FOA) has been extended to later in the current council round. Additionally, the application instructions are modified to remove the "Introduction to Application" as a required element for those applications. Changes to the FOA are shown below.
Key Dates:
Currently Reads:
Open Date: October 17, 2022
Application Due Date: November 17, 2022
Expiration Date: November 18, 2022
Modified to read:
Open Date: November 20, 2022
Application Due Date: December 20, 2022
Expiration Date: December 21, 2022
PHS 398 Research Plan (Overall)
Currently reads:
Introduction to Application: An introduction to Application is required in the Overall component.
Specific Aims: Provide the broad strategic vision, goals, long-term objectives, and the overall structure of the proposed SEIC-T1D to support the Center’s users and T1D research community on a national level.
Modified to read:
PHS 398 Research Plan (Overall)
Specific Aims: Provide the broad strategic vision, goals, long-term objectives, and the overall structure of the proposed SEIC-T1D to support the Center’s users and T1D research community on a national level.
All other aspects of the FOA remain unchanged.
Cheryl K. Nordstrom, PhD, M.P.H.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-402-6711
Email: [email protected]
and Human Services (HHS)
